Feed Top Reports Pricing

⌘K

16:06:05·50d

SECFiling

SEC Form 10-K filed by Verastem Inc.

VSTM· Verastem Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

VSTM
Verastem Inc.
Health Care

Recent analyst ratings

Mar 12UpdateBTIG Research$19.00
Feb 4UpdateH.C. Wainwright$18.00
Oct 16UpdateCantor Fitzgerald-
Apr 10UpdateJefferies$15.00
Mar 24UpdateH.C. Wainwright$10.00
Dec 31UpdateBTIG Research$20.00

Related

PR23h
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
PR14d
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
SEC14d
SEC Form DEF 14A filed by Verastem Inc.
PR21d
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.
INSIDER31d
SEC Form 4 filed by Calkins Daniel
PR37d
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
PR37d
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022